Immunotherapy for Esophageal Cancer - American Cancer Society
Immunotherapy is the use of medicines that help a person’s own immune system find and destroy cancer cells more effectively. It can be used to treat some people with esophageal …
Advancements in immunotherapy for advanced esophageal squamous cell ...
Abstract Introduction: Esophageal cancer (EC), particularly esophageal squamous cell carcinoma (ESCC), is characterized by high incidence and poor prognosis worldwide, necessitating novel …
Neoadjuvant Chemoradiotherapy Plus Immunotherapy in Esophageal Squamous …
Mar 25, 2025 · The disease has an especially high burden in China, where more than half of global cases occur. In East Asia, both neoadjuvant chemoradiotherapy and chemotherapy are …
Future Outlook for PD-1 Inhibitor Use in ESCC and Gastric Cancer
5 days ago · This discussion provides a forward-looking discussion on how the role of PD-1 inhibitors may continue to evolve in the management of esophageal squamous cell carcinoma …
Real-world study of first-line immunotherapy combined with ...
Aug 4, 2025 · This study aimed to assess the effectiveness, safety, and recurrence patterns of first-line immunotherapy combined with chemoradiotherapy in esophageal squamous cell …
How we treat esophageal squamous cell carcinoma - ESMO Open
Feb 13, 2023 · Esophageal squamous cell carcinoma (ESCC) poses a major challenge for clinicians as the prognosis is poor and treatment options are limited. However, recent …
Exploring novel immunotherapy in advanced esophageal squamous cell ...
Jan 23, 2025 · Esophageal squamous cell carcinoma (ESCC) is a prevalent and highly lethal malignancy in Asia. Recent advancements in immune checkpoint inhibitors (ICIs) have …
Rechallenge with immune checkpoint inhibitors for advanced esophageal …
Aug 20, 2024 · Despite the widespread use of immune checkpoint inhibitors (ICIs) in cancer treatment, disease progression remains common in the majority of patients and subsequent …
Revolutionizing Esophageal Squamous Cell Carcinoma Treatment ...
Jul 10, 2024 · The advent of immunotherapy has significantly transformed the treatment paradigm for esophageal carcinoma. The adjuvant therapy study CheckMate-577 showcased the PD-1 …
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment …
1 day ago · in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell …